Ipamorelin and CJC-1295 are frequently studied together because they work through complementary mechanisms — Ipamorelin acts as a GHRP (growth hormone releasing peptide) while CJC-1295 is a GHRH analogue. Together they produce a more robust and sustained GH pulse than either compound alone.
Ipamorelin binds to the ghrelin receptor (GHSR-1a) and stimulates pulsatile GH release with high selectivity — it does not significantly raise cortisol or prolactin. CJC-1295 (with DAC) binds to GHRH receptors on somatotrophs and extends the half-life of endogenous GHRH signaling. When combined, the two compounds act on different receptor populations, producing additive stimulation of GH secretion.
Preclinical studies in rodents show that combining a GHRP with a GHRH analogue produces 2–10x greater GH release than either peptide alone. A 2006 clinical trial of CJC-1295 demonstrated sustained GH and IGF-1 elevation over 6 days. No direct human RCTs exist for the combination, but the mechanistic rationale is well-established in the growth hormone literature.
There is no research basis for timing or amounts: the combination has not been studied as a pair, and the "before sleep" and split-dose schedules online come from forums. Compound Review does not publish dosing or timing protocols. Both compounds are sold for laboratory research only and are not for human or animal consumption.
The safety of the combination has not been studied. Effects reported for the GH axis in general include fluid retention, headache and flushing, and repeated stimulation can blunt the GH response in animal studies. Research-grade products are made without pharmaceutical oversight, so purity and dose accuracy depend entirely on the vendor’s certificates.
They act on different receptors (Ipamorelin on the ghrelin receptor, CJC-1295 on the GHRH receptor), and in studies of GHRH and GHRP pairs in general, giving one of each produced a larger GH response than either alone. That is a hormone measurement; the pair itself has never been trialled for any outcome in people.
No. The ratios and per-injection amounts that circulate online come from forums and vendor marketing, not trials. Neither compound is approved, and no dose has been established for either, alone or combined. Compound Review does not publish dosing or stack protocols.
DAC (drug affinity complex) lets CJC-1295 bind albumin in the blood, stretching its half-life to roughly 6–8 days in early human studies; without DAC (often sold as “modified GRF 1-29”) it lasts about 30 minutes. That changes how GH is released (sustained versus pulsed). It is a pharmacokinetic difference, not guidance on how to use either.
No. CJC-1295 raised GH and IGF-1 in early human pharmacokinetic studies, but no trial has measured body composition, recovery or any other outcome for CJC-1295 with Ipamorelin. Timelines quoted online are anecdotes.
Purgo Labs provides research-grade peptides with independent third-party COAs and >99% purity verification.
Shop Purgo Labs